News

A repeal of key provisions of the health law could lead to significant economic disruption and substantial job losses in every state, according to a new study.

Healthcare leaders share their top book recommendations.

HHS secretary nominee Tom Price has voiced opposition to bundled payments. One expert talks about mandatory and the possibility of voluntary bundled payments.

One study shows that the way Medicare is paying for joint replacements is saving millions of dollars annually and keeping patients satisfied, too.

FDA recently expanded the use of antihemophilic factor (recombinant), pegylated (Adynovate, Shire plc) for hemophilia A patients under 12 years old.

Consumer health groups are praising Health and Human Services’ (HHS) new rule on the Medicaid 340B drug discount program, which sets a ceiling on drug prices.

Experts discuss four of the biggest concerns managed healthcare executives have about repealing the ACA.

By deploying a proactive, year-round strategy that aligns data analytics with a focused approach for addressing gaps in care, your organization can turn routine quality measurement and reporting activities into a true strategic advantage by ensuring that quality measurably improves across key metrics.

Connected devices and apps eliminating the need for manual tracking drive better long-term engagement in healthy activities, a study from Walgreens and Scripps Translational Science, shows.

Although CMS released the final rule for MACRA in October, there is still quite a bit of confusion.

As stakeholders anxiously await the impact of a Trump administration agenda, there is at least one safe bet that all can make.

Managed Healthcare Executive’s 2017 Technology Survey findings reveal that more healthcare executives see the value in telemedicine reimbursement.

The ACA, Medicare, Medicaid, the Children’s Health Insurance Program, and prescription drugs are in the sights of many who will soon be running Washington.

Find out about the latest treatment and drug pipeline developments

This year’s J.P. Morgan Healthcare Conference will address some of the biggest managed care trends, including next-gen at-risk contracts and access to therapy as cancer trends towards a chronic condition.

FDA recently expanded approval of the G5 Mobile Continuous Glucose Monitoring System (Dexcom) to allow for replacement of fingerstick blood glucose (sugar) testing for diabetics.

While FDA approved far fewer new drugs in 2016 than 2015, the agency quickly approved novel and breakthrough therapies.

While every new year brings change, with Donald Trump elected to become the next president, managed healthcare executives will see more changes than usual in 2017.

Managed care organizations may be the next target of value-based reimbursements, with bonus payments tied to the health of their company-and its members.

Some health plans are finding success with a new program that rewards patients for seeking out cheaper care.

When it comes to clinicians discussing end-of-life care with patients and their families, too often decisions must be made quickly. Here’s how data analytics can help.

High drug prices continue to plague payers, but various contributing factors intensify the problem.

Find out what’s in the drug pipeline for autoimmune disease.

Managed Healthcare Executive's most popular articles this year shed light on the biggest areas of interest to managed care organizations. Read more.

FDA recently approved rucaparib (Rubraca, Clovis Oncology) tablets to treat patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer, who have been treated with 2 or more chemotherapies.

FDA approved nusinersen (Spinraza, Biogen), the first drug to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

Deaths due to opioid abuse have risen sharply-and show no signs of leveling off. Here’s how data analytics can prevent abuse and diversion.

While the second feed may not change providers’ actions in terms of the strategy they’re implementing for the Comprehensive Care for Joint Replacement program, the findings should change their expectations.

Find out how healthcare executives feel about the industry moving into 2017.

Adding non-opioid postsurgical options to hospital formularies should be a top consideration.